Cargando…
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
BACKGROUND: Bispecific T-cell engaging antibodies (BiTES), comprising dual anti-CD3 and anti-tumor antigen scFv fragments, are important therapeutic agents for the treatment of cancer. The dual scFv construct for BiTES requires proper protein folding while their small molecular size leads to rapid k...
Autores principales: | Kujawski, Maciej, Li, Lin, Bhattacharya, Supriyo, Wong, Patty, Lee, Wen-Hui, Williams, Lindsay, Li, Harry, Chea, Junie, Poku, Kofi, Bowles, Nicole, Vaidehi, Nagarajan, Yazaki, Paul, Shively, John E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727398/ https://www.ncbi.nlm.nih.gov/pubmed/31488104 http://dx.doi.org/10.1186/s12885-019-6056-8 |
Ejemplares similares
-
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012) -
Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
por: Minnix, Megan, et al.
Publicado: (2020) -
Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020) -
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021) -
TEs or not TEs? That is the evolutionary question
por: Vaknin, Keren, et al.
Publicado: (2009)